Analytical Data
-
Gene name
SYNRg
- Application
-
Alternative Names
SYNRg；AP1GBP1；SYNG；Synergin gamma
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UMZ2
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SYNRg, a recombinant protein, has garnered significant attention in recent years due to its potential applications in various biomedical fields. The understanding of protein interactions and their roles in cellular processes has propelled research into engineered proteins that can mimic or modulate these interactions. SYNRg, specifically, is engineered to enhance synaptic functions and neural communication, making it a promising candidate for studies related to neurodegenerative diseases and mental health disorders. The increasing prevalence of such conditions has underscored the urgent need for novel therapeutic strategies, driving research into SYNRg’s biochemical properties and its effects on neural networks. Through recombinant DNA technology, SYNRg is produced in controlled laboratory settings, allowing for the manipulation of its structure and activity to optimize its therapeutic efficacy. Studies have indicated that SYNRg can influence pathways involved in synaptic plasticity, potentially leading to improvements in cognitive function. Additionally, its ability to cross the blood-brain barrier presents further opportunities for developing targeted treatments. Ongoing research aims to elucidate the full spectrum of SYNRg's biological functions, assess its safety and efficacy in preclinical models, and ultimately advance it towards clinical applications. The exploration of SYNRg's capabilities represents a crucial step in the quest for innovative solutions to address the challenges posed by neurological disorders, paving the way for a deeper understanding of synaptic dynamics and potential breakthroughs in therapy.
